Discovery Of Methylated Circulating DNA Biomarkers For Comprehensive Non-Invasive Monitoring Of Treatment Response In Metastatic Colorectal Cancer

摘要

ObjectiveThe evaluation of mutations in cell free circulating DNA (cfDNA) has recently been used for tracking disease relapse in colorectal cancer (CRC). This approach requires personalized assay design due to the lack of universally mutated genes. In contrast, early methylation alterations are restricted to defined genomic loci allowing comprehensive assay design for population studies. Our objective was to identify cancer specific methylated biomarkers which could be measured longitudinally in cfDNA to monitor therapeutic outcome in metastatic CRC patients (mCRC).